glp-1 and gip dual agonist This review summarizes how GIP/GLP-1 receptor agonists act at the cellular level and their therapeutic applications in metabolic diseases like type 2 diabetes and obesity, highlighting advances in incretin-based Science Behind GLP 1 GIP

We have an obligation to understand the full biology of these drugs, not just the intended effect

W., Thielke, D., Viljoen, A., & McCrimmon, R

however, anti-drug antibodies have not been shown to impact drug effects in diabetes

& Voga, G

Acknowledgements This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License ( which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made